- $10.63bn
- $9.78bn
- $475.42m
- 100
- 11
- 99
- 80
Annual income statement for Doximity, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 116 | 207 | 344 | 419 | 475 |
Cost of Revenue | |||||
Gross Profit | 101 | 176 | 304 | 366 | 425 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 94.2 | 154 | 230 | 294 | 312 |
Operating Profit | 22.2 | 53.3 | 114 | 125 | 164 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 23.5 | 57.8 | 114 | 133 | 185 |
Provision for Income Taxes | |||||
Net Income After Taxes | 29.7 | 50.2 | 155 | 113 | 148 |
Net Income Before Extraordinary Items | |||||
Net Income | 29.7 | 50.2 | 155 | 113 | 148 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 10.8 | 21.6 | 133 | 113 | 148 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.061 | 0.121 | 0.698 | 0.529 | 0.748 |